-
Blood: The cost-effectiveness of using Ilutinib as a first-line therapy in CLL patients
Time of Update: 2020-06-16
The ALLIANCE trial found that the continued use of ilutinib significantly extended the patient's progression-free survival compared to the treatment of elderly patients with chronic lymphocytic leuke
-
High mortality rate for heart injury associated with this tumor treatment! Summary of Foreign Scholars
Time of Update: 2020-06-16
Immune checkpoint inhibitors such as monoclonal antibody therapy for cytotoxic T lymphocyte-related antigens 4 (CTLA-4), procedural death receptor-1 (PD-1) and their ligands have become the standard
-
"Doctor, fentanyl-to-skin painkillers are not 'aonosic', is it useful for tumor pain in the end?"
Time of Update: 2020-06-16
Fentanyl transdermal patches (aka Dorigi paste, commonly known as painkillers) are not anti-inflammatory analgesic saines in the mouths of ordinary people, although they all have analgesic effect, bu
-
ASCO 2020 . . . Upstart: Targeting PD-L1 precursor therapy drug CX-072
Time of Update: 2020-06-16
This year ASCO's new PD-L1 antibody data code-named CX-072 was released, from the results of the study, its safety is excellent, more intimate is the target PD-L1 precursor treatment drug CX-072 "ins
-
BMC Cancer: Association of Breast Cancer and Intestinal Microbiome Disorders with Breast Cancer Risk
Time of Update: 2020-06-16
Breast cancer ranks first among women and the second leading cause of death in this sex In addition to genetic factors, the environment is one of the causes of the disease, although the factors are n
-
Merck's PD-1 monoanti-Keytruda combined chemotherapy for advanced urinary skin cancer, Phase III clinical failure
Time of Update: 2020-06-16
Merck announced that its PD-1 monoanti-Keytruda (pembrolizumab) combination of first-line chemotherapy treatment for patients with advanced or metastatic urethra skin cancer in Phase III clinical lys
-
CAR-T Cell Therapy and Bispecific Antibody Resustomino: Roche signs $2 billion partnership agreement with Cinda Bio
Time of Update: 2020-06-16
Swiss pharmaceutical giant Roche has reached an agreement with Innovention Biologics to develop a common CAR-T cell therapy and 2:1 T-cell bispecific antibodies for blood and solid cancers Roche's 2
-
NEJM: Emery's therapeutic effect on early breast cancer is significant
Time of Update: 2020-06-16
Patients with invasive breast cancer who underwent new assisted chemotherapy plus human epidermal growth factor receptor 2 (HER2) targeted treatment had a worse prognosis than patients without residu
-
Blood: New risk scoring method for predicting event-free survival rates after allo-HCT in patients with sickle cell disease
Time of Update: 2020-06-16
Ruta et al developed a risk score to predict the event-free survival rate (EFS; probability of implantation in a donor) after transplantation of allogeneic hematopoietic cells in patients with sickle
-
National initiative: autonomous breathing needle sting complex anesthesia and thoracic tracheotomy malignancy removal
Time of Update: 2020-06-16
On June 3, xi'an Jiaotong University First Affiliated Hospital successfully carried out the country's first autonomous respiratory needle compound anesthesia chest cavity tracheotomy excision, so tha
-
FC-optimized HER2 single-fight Margetuximab treats stomach cancer, receives FDA award for orphan drug
Time of Update: 2020-06-16
MacroGenics announced that the U.S Food and Drug Administration (FDA) has awarded the Orphan Drug (ODD) to its single-resistant margetuximab, which targets HER2, to treat cancer in the stomach and ga
-
Blood: Effects of DHFR and FPGS germ cell mutations on methotrexate metabolism and RISK OF ALL recurrence
Time of Update: 2020-06-16
Methotrexate (MTX) maintenance therapy is critical for the treatment of acute lymphoblastic leukemia (ALL), but achieving appropriate treatment doses with individual differences remains a challenge w
-
A major breakthrough in science! A lot of bacteria were found in the tumor!
Time of Update: 2020-06-16
How do they promote or hinder the growth of cancer?
What are their effects on the response to various cancer treatments?
-
What dose is appropriate for elderly and infirm lung cancer patients?
Time of Update: 2020-06-16
In the International Journal of Cancer, European Journal of Cancer and other published SCI papers 65, the cumulative impact factor of about 300 points, of which the first or the first author of THE S
-
PNAS: New engineered protein seq.com blocks cancer from growing and regenerating neurons
Time of Update: 2020-06-16
Ligands are protein molecules that transmit signals between or within cells Ligands work by binding to a cell protein called a receptor After binding to the ligand, the receptor can send additional s
-
Ann Oncol: OlympiAD's final overall survival and tolerance results
Time of Update: 2020-06-16
In the OlympiAD study, olapani was shown to improve progressive survival metastatic breast cancer (mBC) compared to chemotherapy with a reproductive BRCA1 and/or BRCA2 mutation (BRCAAm) and a human e
-
Professor Li Jin's own account: a conscience can become a good doctor
Time of Update: 2020-06-16
Since i have become a doctor, this life to save people is my job, but also the source of my life, nothing else Although the World Health Organization has long defined cancer as a chronic disease, the
-
Mid-term analysis of DESTINY-Lung01 in Phase II trials showed meaningful clinical activity in the treatment of HER2 mutant non-small cell lung cancer patients, with 61.9% of patients receiving tumor remission
Time of Update: 2020-06-06
The results of the ongoing Phase II clinical trial destinY-Lung01 show that AstraZeneca and The Third Of AstraZeneca have achieved clinical lying in patients with one or more systems treated with o
-
Lung cancer! AstraZeneca Imfinzi (Infyfan) first-line treatment of wide-term small cell lung cancer (ES-SCLC) continues to significantly extend the total survival!
Time of Update: 2020-06-06
May 31, 2020 / Biovalley BIOON/--- Astra Zeneca recently announced the results of the latest analysis of the CASPIAN trial in Phase III of Lung Cancer The data show that the anti-PD-L1 therapy I
-
Colorectal cancer precision medicine! Mersadon Keytruda first-line treatment of MSI-H/dMMR patients head-to-head Phase III efficacy beats standard chemotherapy!
Time of Update: 2020-06-06
May 30, 2020 / PRNewswire BIOON/-- Merck and Co recently released positive results for the first time in the key phase III KEYNOTE-177 study The study is evaluating the anti-PD-1 therapy Keytruda